$SNOA

Sonoma Pharmaceuticals, Inc. (SNOA) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Sonoma Pharmaceuticals, Inc. 8-K false 0001367083 0001367083 2026-08-19 2026-08-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities E

Sonoma Pharmaceuticals reported first-quarter revenue of $6.4 million, up from $4.0 million a year earlier, with U.S. sales up 141% to drive growth. Gross profit rose to $2.6 million (40% margin). EBITDA turned positive at $0.1 million versus a $1.0 million loss. Cash was $5.3 million as of June 30, 2026. Shares rose to $1.24 premarket.

Sonoma Pharmaceuticals (Nasdaq:SNOA) reported fourth-quarter FY2026 results for the quarter ended March 31, 2026. Revenue rose to $5.6M (+48%) from $3.8M; gross profit was $2.2M (39%). Net loss was $0.6M, and EBITDA loss improved 66% to $0.2M. For FY2026, revenue increased to $19.5M (+$5.2M) and EBITDA loss fell 38% to $2.1M. Cash was $2.4M.

Sonoma Pharmaceuticals has closed a public unit offering, raising approximately $3.5 million in net proceeds after expenses. The offering included units of common stock or pre-funded warrants, complemented by common stock purchase warrants, with each unit priced at $1.35. The funds are earmarked for general corporate purposes and working capital.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Sonoma Pharmaceuticals (SNOA) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.